Related Experiment Video
Updated: May 24, 2026
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
Cognitive stimulation to improve cognitive functioning in people with dementia
Bob Woods1, Elisa Aguirre, Aimee E Spector
1Dementia ServicesDevelopment CentreWales, Bangor University, Bangor, UK. b.woods@bangor.ac.uk.
The Cochrane Database of Systematic Reviews
|February 17, 2012
Summary
Cognitive stimulation programs consistently improve cognitive function in individuals with mild to moderate dementia. These benefits, including enhanced quality of life and social interaction, were observed immediately after treatment and maintained for up to three months.
Area of Science:
- Neuroscience
- Gerontology
- Psychology
Background:
- Cognitive stimulation (CS) is an intervention for dementia, evolving from Reality Orientation (RO).
- CS aims to enhance thinking, concentration, and memory in a social setting.
- Evidence-based practice necessitates a systematic review of CS effectiveness in dementia care.
Purpose of the Study:
- To evaluate the effectiveness of cognitive stimulation interventions for people with dementia.
- To assess the impact of CS on cognitive function and other outcomes.
- To identify any potential negative effects associated with CS.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) identified through the ALOIS register and other databases.
- Included RCTs focused on cognitive stimulation for dementia with measures of cognitive change.
- Data extraction and risk of bias assessment were performed independently by two reviewers.
Main Results:
- Fifteen RCTs involving 718 participants were included; study quality was generally low.
- Cognitive stimulation showed a consistent benefit on cognitive function (SMD 0.41, 95% CI 0.25 to 0.57), maintained at 1-3 months follow-up.
- Secondary analyses indicated benefits in self-reported quality of life and staff-rated communication/social interaction, with no significant effects on mood or daily living activities.
Conclusions:
- Cognitive stimulation programs consistently benefit cognition in mild to moderate dementia.
- Improvements in quality of life and well-being are promising, warranting further exploration.
- Further research is needed on long-term benefits and clinical significance of CS programs.
Related Concept Videos
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...